Novartis' Zelnorm Approved For Chronic Constipation Without Gender Restrictions
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA approves the supplemental indication despite an advisory committee recommendation that tegaserod use be limited to women. The agency follows the committee's recommendation on use only in individuals under age 65.
You may also be interested in...
Novartis Further Restricts Access To Zelnorm
Irritable bowel syndrome therapy available in U.S. only for emergencies.
Novartis Further Restricts Access To Zelnorm
Irritable bowel syndrome therapy available in U.S. only for emergencies.
Zelnorm Will Be Available Under Treatment IND Following Marketing Suspension
Novartis voluntarily suspends marketing of the irritable bowel syndrome medication due to cardiovascular events.